Cargando…

Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis

Background: Fabry disease is an inherited lysosomal storage disease affecting multiple organs with complications, including cardiomyopathy such as left ventricular hypertrophy (LVH). Enzyme replacement therapy (ERT) has been the main treatment for Fabry patients since 2001. However, the indications...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chung-Lin, Lin, Shuan-Pei, Niu, Dau-Ming, Lin, Hsiang-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692116/ https://www.ncbi.nlm.nih.gov/pubmed/34975306 http://dx.doi.org/10.7150/ijms.66448

Ejemplares similares

ERT impact on left ventricular mass in Fabry disease
por: Ortiz, Alberto
Publicado: (2019)

Difficulties in Diagnosing Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy (LVH): Is the Novel GLA Gene Mutation a Pathogenic Mutation or Polymorphism?
por: Aladağ, N, et al.
Publicado: (2023)

Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014)

The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): rationale, potential and challenges
por: BoonPeng, Hoh, et al.
Publicado: (2013)

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
por: Brown, Alexander J M, et al.
Publicado: (2020)

Assessment of Left Ventricular Hypertrophy (LVH) Criteria by Surface Electrocardiography in a Sample of Iraqi Patients with Systemic Arterial Hypertension
por: Altaweel, Rafid Bashir, et al.
Publicado: (2020)

Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)
por: Lin, Hsiang-Yu, et al.
Publicado: (2013)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset fabry mutation (IVS4 + 919G > A)
por: Hsu, Ting-Rong, et al.
Publicado: (2014)

Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease
por: Fujii, Hideki, et al.
Publicado: (2012)

Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy
por: Kim, Woo-Shik, et al.
Publicado: (2019)

Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy
por: Sadasivan, Chandu, et al.
Publicado: (2020)

The association between annexin A5 (ANXA5) gene polymorphism and left ventricular hypertrophy (LVH) in Chinese endogenous hypertension patients
por: Zhang, Bei, et al.
Publicado: (2017)

ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
por: Kozor, Rebecca, et al.
Publicado: (2016)

Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis
por: Yousef, Zaheer, et al.
Publicado: (2013)

Aortic Root Dilatation in Taiwanese Patients with Mucopolysaccharidoses and the Long-Term Effects of Enzyme Replacement Therapy
por: Lin, Hsiang-Yu, et al.
Publicado: (2020)

Natural progression of cardiac features and long-term effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis II
por: Lin, Hsiang-Yu, et al.
Publicado: (2021)

Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
por: Baptista, Ana, et al.
Publicado: (2015)

Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)
por: Liu, Hao-Chuan, et al.
Publicado: (2014)

Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation
por: Chien, Yueh, et al.
Publicado: (2016)

Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy
por: Gaggl, Martina, et al.
Publicado: (2016)

Mono-symptomatic Fabry disease in a population with mild-to-moderate left ventricular hypertrophy
por: Fuller, Maria, et al.
Publicado: (2020)

Left Ventricular Apical Aneurysm in Fabry Disease: Implications for Clinical Significance and Risk Stratification
por: Chang, Hao‐Chih, et al.
Publicado: (2022)

Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases
por: Ivanova, Margarita M., et al.
Publicado: (2019)

Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study　― Protocol for a Multicenter, Open-Label, Exploratory Interventional Study ―
por: Sueta, Daisuke, et al.
Publicado: (2022)

Ascending aorta dilatation common feature which correlate with left ventricular hypertrophy in fabry disease
por: Bensalah, Mourad, et al.
Publicado: (2011)

Unexplained Left Ventricular Hypertrophy Diagnosed as a Cardiac Variant of Late-Onset Fabry Disease: A Case Report
por: Zhao, Maomao, et al.
Publicado: (2023)

Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study in Turkey
por: Barman, Hasan Ali, et al.
Publicado: (2020)

Intramural Reentrant Ventricular Tachycardia in a Patient with Severe Hypertensive Left Ventricular Hypertrophy
por: Lin, Chin-Yu, et al.
Publicado: (2015)

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series
por: Lin, Hsiang-Yu, et al.
Publicado: (2016)

Evaluation of muscle biopsy in late-onset GSDII patients before and after enzyme replacement therapy (ERT)
por: Violano, R, et al.
Publicado: (2013)

Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease
por: Sayeed, Nadia, et al.
Publicado: (2015)

Estrogen replacement therapy (ERT) in high-risk cancer patients.
por: Hutchinson-Williams, K. A., et al.
Publicado: (1991)

Association of Arterial Stiffness and Electrocardiography-Determined Left Ventricular Hypertrophy with Left Ventricular Diastolic Dysfunction
por: Hsu, Po-Chao, et al.
Publicado: (2012)

Rationale and design of a multicentre, randomized, placebo‐controlled trial of mirabegron, a Beta3‐adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3‐left ventricular hypertrophy (Beta3‐LVH)
por: Pouleur, Anne‐Catherine, et al.
Publicado: (2018)

Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis
por: Alegra, Taciane, et al.
Publicado: (2012)

Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease
por: Pogoda, Christian, et al.
Publicado: (2023)

S2.1 Enzyme replacement therapy (ERT) in Glycogen Storage Disease Type II: the first treatment developed
por: Angelini, Corrado, et al.
Publicado: (2011)

Left ventricular hypertrophy detection using electrocardiographic signal
por: Liu, Cheng-Wei, et al.
Publicado: (2023)

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_c4461cceolg1o2edi4ecl5caad